Modeling the effectiveness of mass cholera vaccination in Bangladesh

Similar documents
Mathematical modeling of cholera

Oral Killed Whole Cell Vaccines: review of available evidence of vaccine effectiveness and safety across different settings and age groups

Technical Note. November 2016

Technical Note. 13 January 2016

5th Meeting of the Initiative against Diarrheal & Enteric diseases in Asia IDEA

Update on the Use of Oral Cholera Vaccines (OCV) and Integration with WaSH: Challenges and Opportunities

BIOST/STAT 578 A Statistical Methods in Infectious Diseases Lecture 16 February 26, Cholera: ecological determinants and vaccination

Mathematical modelling of infectious disease transmission

Modeling results / SDF: Routine vaccination strategy Introduction catch-up strategy

Cholera Vaccine and Behavior Change Trial Outcome Measurements. Steve Luby WSH Evaluation Convening University of California, Berkeley March 31, 2011

No

Herd Protection- Efficacy vs effectiveness The Importance of Cluster-Randomized Trials to assess Vaccine Herd Protection

Examining the Role of Social Networks and Herd Immunity in a Cholera Vaccine Trial in Bangladesh

Recent WHO Data (2002)

COUNTRY NAME: BANGLADESH. GTFCC 5-6 Dec 2018

COUNTRY NAME: BANGLADESH. 5 th Annual Meeting of the GTFCC June 2018

Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis

Challenges of use of cholera vaccines in Haiti and the Americas

Estimating impact and cost-effectiveness of ending cholera roadmap

Cholera vaccines: an update. Dipika Sur MD Consultant Translational Health Science and Technology Institute, INDIA Former Scientist 'G' ICMR

The Case for Reactive Mass Oral Cholera Vaccinations

Determining the Feasibility of an Oral Cholera Vaccination (OCV) Campaign

Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial

Concepts of herd protection and immunity

Global deployment of Oral Cholera Vaccine (OCV) Dipika Sur MD Consultant THSTI, India

Why is surveillance important after introducing vaccines?

Cholera. Report by the Secretariat

Vibriocidal Antibody Responses to a Bivalent Killed Whole-Cell Oral Cholera Vaccine in a Phase III Trial in Kolkata, India

Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings

Beyond effectiveness: research on vaccines seen as a continuum

Mathematical Models for the Control of Infectious Diseases With Vaccines

Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity

Critical immunity thresholds for measles elimination

Modelling screening of HPV vaccinated birth cohorts. The infection transmission system

IVI Cholera Activities

Cholera Clinical Guidelines. OAHPP Rounds January 11, 2011 Vanessa G. Allen MD FRCPC Medical Microbiologist

Lopez, AL; Deen, J; Azman, AS; Luquero, FJ; Kanungo, S; Dutta, S; von Seidlein, L; Sack, DA

Frequently Asked Questions

Cholera Epidemiological study in the East and Southern Africa region UNICEF ESARO study

Glossary of Terms Related to Cholera and Cholera Vaccine Programs

Background Paper on Whole-Cell, Killed, Oral Cholera Vaccines

The design and analysis of Phase IIb Ebola vaccine trials

Report to the Board 6-7 June 2018

What do epidemiologists expect with containment, mitigation, business-as-usual strategies for swine-origin human influenza A?

Emergency type: Rohingya Refugee Crisis

Cholera at the Crossroads: The Association Between Endemic Cholera and National Access to Improved Water Sources and Sanitation

Assessment of dengue vaccine effectiveness and impact for different rollout strategies

Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov

How to talk about typhoid: menu of messages

Immunization and Vaccines

Herd Protective Effects of Vaccines. John Clemens icddr,b, Dhaka, Bangladesh

Copenhagen, Denmark, September August Malaria

Existing interventions on cholera Prevention and control

WHO perspective and guidance on burden of dengue, prevention and control and integrated management

FMD Control Initiatives in Bangladesh

Epidemic and Endemic Cholera Trends over a 33-Year Period in Bangladesh

Gavi s Vaccine Investment Strategy

REGIONAL FRAMEWORK FOR THE IMPLEMENTATION OF THE GLOBAL STRATEGY FOR CHOLERA PREVENTION AND CONTROL, Report of the Secretariat

Role of vaccination and the evaluation of LSD control programmes

Emergency type: Rohingya Refugee Crisis

How does Gavi make vaccine investment decisions?

Martin, S; Lopez, A L; Bellos, A; Deen, J; Ali, M; Alberti, K; Anh, D D; Costa, A; Grais, R; Legros, D; Luquero, F J; Ghai, M B; Perea, W; Sack, D A

Vaccine Efficacy, Effectiveness and Impact. G. HANQUET, KCE, 9 September 2017

Experiences with pre-emptive cholera vaccination in emergency situations

Mathematical Model of Vaccine Noncompliance

Parker, LA; Rumunu, J; Jamet, C; Kenyi, Y; Lino, RL; Wamala, JF; Mpairwe, AM; Ciglenecki, I; Luquero, FJ; Azman, AS; Cabrol, JC

Okinawa, Toyako, and Beyond: Progress on Health and Development

GAVI S CONTINUED ROLE IN YELLOW FEVER CONTROL

Sudan del Sur: Guerra, Hambre y Cólera Otra vez!

WHO Consultation on oral cholera vaccine (OCV) stockpile strategic framework: potential objectives and possible policy options

Generating potential demand and impact estimates to inform dengue vaccine introduction in Brazil and Mexico

Updated WHO position paper on pertussis vaccines. Geneva, Switzerland October 2010

FMD VACCINES AND THEIR USE IN VACCINATION PROGRAMMES: THEORY AND PRACTICE

Assessing public health impact through vaccine probe analyses. Robert F. Breiman Emory Global Health Institute Emory University

in control group 7, , , ,

Measles Strategic Planning Tool: Analysis of MCV strategies in developing countries. Emily Simons 29 January 2009

Cost-Effectiveness of New-Generation Oral Cholera Vaccines: A Multisite Analysisvhe_

EVIDENCE TO RECOMMENDATIONS TABLE i - TYPHOID VACCINES

Case Studies in Ecology and Evolution. 10 The population biology of infectious disease

Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa

Correlates of Protection against Enterotoxigenic Escherichia coli

Current Status of PCV Use and WHO Recommendations

California 2010 Pertussis Epidemic. Kathleen Winter, MPH Immunization Branch California Department of Public Health

Edwin J. Asturias Associate Director

Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis

Epidemiology of Diarrheal Diseases. Robert Black, MD, MPH Johns Hopkins University

Report to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid

MODELLING INFECTIOUS DISEASES. Lorenzo Argante GSK Vaccines, Siena

HEALTH CLUSTER. Summary Report. Prioritization of woredas for the drought related emergency health response. Dereje Ayana 2/22/2016

Essentials of Aggregate System Dynamics Infectious Disease Models. Nathaniel Osgood CMPT 858 FEBRUARY 3, 2011

e-bug: Vaccinations Teacher Sheet Student worksheet 1 answers

UNICEF Strategic Framework for Cholera in Eastern and Southern Africa:

Study population The study population comprised the general population of Senegal inhabitants aged 1 to 30 years.

Mathematical Structure & Dynamics of Aggregate System Dynamics Infectious Disease Models 2. Nathaniel Osgood CMPT 394 February 5, 2013

Progress and Challenges of Enteric Vaccines. Dr. Tajul Islam A Bari icddr,b Bangladesh

Polio and measles control: opportunities and threats for health systems

Cost-effectiveness of controlling infectious diseases from a public health perspective Krabbe Lugnér, Anna Katarina

Diphtheria Outbreak Response Cox s Bazar Bangladesh

Infectious Disease Models 4: Basic Quantities of Mathematical Infectious Disease Epidemiology. Nathaniel Osgood CMPT

GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights

Transcription:

Modeling the effectiveness of mass cholera vaccination in Bangladesh Dennis Chao April 20, 2016 1 / 20

Vibrio cholerae in Bangladesh Ali et al. Updated Global Burden of Cholera in Endemic Countries. PLoS NTDs. 2015. Dhaka, Bangladesh Cholera is endemic around the Bay of Bengal. Vibrio cholerae is part of the estuarine ecosystem. The toxin adopted by V. cholerae causes cholera. 2 / 20

Burden of cholera in Bangladesh *International Vaccine Institute. Country investment case study on cholera vaccination: Bangladesh. 2012. Glass et al. Endemic cholera in rural Bangladesh, 1966 1980. Am J Epidemiol 116(6):959 70. 1982. Estimated 350,000 cases and 5,300 deaths per year in Bangladesh. Cholera incidence is about 1 4 per 1000 per year. Cholera activity peaks before or after monsoons. 3 / 20

How can cholera transmission be stopped? Data from http://app.dghs.gov.bd/localhealthbulletin2015/publish/ The long-term solution is improved hygiene and sanitation (WASH). Oral cholera vaccine (OCV) may be part of a short-term solution. 4 / 20

Cholera vaccine 3 World Health Organization pre-qualified vaccines: Dukoral (2001) Shanchol (2011) Euvichol (2015) Cholera vaccine is not expensive (about $1.85 per dose), and having a local manufacturer would make it even cheaper. Good acceptability in Bangladesh. Cholera vaccination in Dhaka, Bangladesh by Orlando de Guzman and Andrew Marshall 5 / 20

Using cholera vaccine efficiently Bangladesh has 166 million people. 1 2 million doses of OCV available worldwide. Target cholera hot-spots? About half of Bangladesh can be considered high-risk. Prioritize children for vaccination? About 50 million children under 15 years old. Birth cohort is over 3 million. An investment case for the accelerated introduction of oral cholera vaccines. The International Vaccine Institute. 2012 Cholera vaccine has moderate efficacy (65%) that may last 3 to 5 years. Need for regular boosters could be expensive. Lowest efficacy among young children, who have the highest incidence of disease. 6 / 20

What is the efficacy of cholera vaccine? Fong, Halloran, Park, Marks, Clemens, Chao. Efficacy of a Bivalent Killed Whole-Cell Cholera Vaccine Over Five Years: A Reanalysis of a Cluster-Randomized Trial. In submission. We re-analyzed cholera vaccine trial data to study efficacy by age and over time. Vaccine is less effective in those vaccinated when under 5 years old (38%) and most effective in older children (85%). Didn t see evidence of waning efficacy among adults. Adults might not require boosters after only 5 years. 7 / 20

Direct protection from vaccine X Vaccinated people are less likely to become infected. (about 65% less) 8 / 20

Indirect protection from mass vaccination X X Vaccinated people are less likely to become infected and less likely to infect others. Therefore, vaccines can protect vaccinated and unvaccinated people. (Also applies to WASH interventions.) 9 / 20

Herd immunity, or protecting the unvaccinated Incidence per 1000 population 12 10 8 6 4 2 0 Direct protection Observed Model fit 0% 20% 40% 60% 80% 100% Vaccination coverage 1985 OCV trial in Matlab: 49336 vaccinees, 24667 placebo. If a vaccine is 65% effective, then one should avert at least 65% of cases. The observed reduction in a large-scale trial was greater. High levels of vaccination (but below 100%) can basically stop cholera transmission ( herd immunity ). 10 / 20

Mathematical model of cholera in Bangladesh birth Susceptible unvaccinated x x waning waning natural death Vaccinated natural death Infected Recovered x x + Environment decay We developed a mathematical model of cholera transmission calibrated to the dynamics and epidemiology of cholera in Matlab, Bangladesh. Mathematical models can capture direct and indirect protection. Includes waning immunity (Recovered to Susceptible transition) and vital dynamics. Dimitrov, Troeger, Halloran, Longini, Chao. Comparative effectiveness of different strategies of oral cholera vaccination in Bangladesh: A modeling study. PLoS Negl Trop Dis 8(12): e3343. 11 / 20

Modeling mass vaccination Epidemic curves Overall effectiveness Dimitrov DT, Troeger C, Halloran ME, Longini IM, Chao DL. Comparative effectiveness of different strategies of oral cholera vaccination in Bangladesh: A modeling study. PLoS Negl Trop Dis 8(12): e3343. We assumed that vaccine protects for 5 years on average. After mass vaccination, incidence goes down for the first year then returns to pre-vaccination levels a few years later. Overall effectiveness starts high then declines. 12 / 20

Targeting geographic hotspots Qadri et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 386:1362 71. 2015. Mirpur (Dhaka, Bangladesh) had the highest incidence of cholera (4 per 1000). Non-pregnant individuals 1 year old and older were invited to participate in a demonstration project. 3 arms: Vaccination, Vaccination+Behavioural, No intervention. 65% coverage was achieved. 13 / 20

Barriers to effective mass vaccination Only 37% overall protection in vaccination only arm. Vaccinated clusters were small and surrounded by untreated individuals. Clusters with 3,000 people. 30-meter buffer zones around clusters. High population mobility. 58% of participants migrated out or died during the two year trial. Qadri et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 386:1362 71. 2015. 14 / 20

Maintaining OCV coverage levels Incidence per 1000 population 12 10 8 6 4 2 0 Observed Direct protection Vaccine waning Births/deaths Model Migration fit 0% 20% 40% 60% 80% 100% Vaccination coverage Erosion of coverage can have a disproportionately large (or small) effect on indirect protection. To prevent large outbreaks, coverage must remain consistently high. 15 / 20

Vaccinate every few years Vaccine coverage Epidemic curves Dimitrov DT, Troeger C, Halloran ME, Longini IM, Chao DL. Comparative effectiveness of different strategies of oral cholera vaccination in Bangladesh: A modeling study. PLoS Negl Trop Dis 8(12): e3343. Vaccinate every few years to compensate for waning and population turnover (births, deaths, and migrations). Average incidence is reduced but large outbreaks still occur when coverage is lowest. How often do we need to vaccinate? Do we need routine vaccination of children between campaigns? 16 / 20

Community-level benefits from protecting children Dimitrov DT, Troeger C, Halloran ME, Longini IM, Chao DL. Comparative effectiveness of different strategies of oral cholera vaccination in Bangladesh: A modeling study. PLoS Negl Trop Dis 8(12): e3343. Young children have the highest incidence of cholera. Vaccinating young children is probably easiest logistically. Vaccinating the whole population, including adults, may prevent the most cases per vaccination. But it may be more difficult and expensive to reach adults. Ongoing trial in Mirzapur will show the community-level protection from vaccinating children (ages 1 15 years). 17 / 20

Cost effectiveness Halloran and Longini. Emerging, evolving, and established infectious diseases and interventions. Science 345(6202):1292 4. 2014. To prevent large outbreaks, coverage must remain consistently high. Even sub-optimal coverage levels can be cost-effective. $3.93 to vaccinate each person (2 doses). Vaccine was 58.5% of the total cost. Khan IA, Saha A, Chowdhury F, Khan AI, Uddin MJ, Begum YA, Riaz BK, Islam S, Ali M, Luby SP, Clemens JD, Cravioto A, Qadri F. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine. 2013 Dec 9;31(51):6058-64. We are talking to public health officials about actual vaccination strategies being considered and the associated costs. 18 / 20

Summary Mass cholera vaccination is feasible in Bangladesh. Developing a cost-effective strategy is challenging. Where to vaccinate? Who to vaccinate? How often to vaccinate? Mathematical models can be informed by trial results. High levels of OCV coverage should produce herd immunity. Will we see high levels of indirect protection from vaccinating only children? How can we maintain high levels of OCV coverage in mobile populations? How to integrate WASH into mathematical models? 19 / 20

Thank you! Colleagues Betz Halloran Dobromir Dimitrov Youyi Fong Chris Troeger Ira Longini John Clemens dennisc@intven.com 20 / 20